Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome

Ocul Immunol Inflamm. 2006 Dec;14(6):333-9. doi: 10.1080/09273940600976938.

Abstract

Purpose: To describe the role of triple agent immunosuppression in severe recalcitrant cases of Vogt-Koyanagi-Harada syndrome.

Materials and methods: Retrospective chart review of five cases of Vogt-Koyanagi-Harada syndrome.

Results: All cases were treated with oral prednisolone, azathioprine, and cyclosporine in combination, and rapid remission was observed in all patients. The synergistic effect of the triple agent immunosuppressives helped in preventing recurrences. Prolonged treatment with steroid sparing immunosuppressives in severe and recalcitrant cases of Vogt-Koyanagi-Harada syndrome maintained disease remission.

Conclusion: Severe cases of Vogt-Koyanagi-Harada syndrome can be treated with early use of high-dose triple agent immunosuppressives.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Azathioprine / therapeutic use*
  • Cyclosporine / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Fundus Oculi
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Middle Aged
  • Ophthalmoscopy
  • Prednisolone / therapeutic use*
  • Remission Induction / methods
  • Retrospective Studies
  • Uveomeningoencephalitic Syndrome / drug therapy*
  • Uveomeningoencephalitic Syndrome / pathology

Substances

  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclosporine
  • Prednisolone
  • Azathioprine